October 10, 2017

Forendo Pharma nominates world class scientific advisory board and elects Professor Linda Giudice as the Chairperson

Turku, Finland, October 10, 2017

Forendo Pharma, a drug development company developing novel oral treatments for endometriosis patients, announces the nomination of its Scientific Advisory Board today. Forendo is developing tissue-specific hormone inhibitors to rebalance local estrogen metabolism in endometrial tissues. The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels as demonstrated in preclinical models. This selective activity is expected to allow safer long-term treatment of this chronic disease without harmful symptoms of estrogen deficiency.